Most Read Articles
Roshini Claire Anthony, 05 Apr 2021

Primary analysis of the D8110C00001 trial showed that the COVID-19 vaccine AZD1222 had 76 percent efficacy at preventing symptomatic COVID-19.

Roshini Claire Anthony, 12 Apr 2021

Treatment with the human monoclonal antibody tezepelumab reduced exacerbations and improved asthma control, lung function, and quality of life in adults and adolescents with severe, uncontrolled asthma, according to the phase III NAVIGATOR study presented as a poster at AAAAI 2021.

Audrey Abella, 16 Mar 2021
Following the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine between December 14 and 23, 2020 in the US, 21 cases of anaphylaxis have been recorded, equating to an initial estimated rate of 11.1 cases/million doses administered, according to a joint report from the US FDA and the CDC* COVID-19 Response Team.
Pearl Toh, 28 Apr 2021
Impaired smell function occurs more commonly in people with mild rather than moderate-to-critical forms of COVID-19 illness, a study finds.

Antibiotics in kids with atopic dermatitis may increase asthma risk

29 Apr 2021

Early-life exposure to antibiotics seems to worsen the risk of asthma in children with atopic dermatitis (AD), a recent study has found.

Drawing from the Longitudinal Health Insurance Database of Taiwan, the researchers enrolled AD patients younger than 6 years of age. After 1:3 matching, the final cohort included 1,251 children who developed asthma, defined as cases, and 3,753 participants who did not, defined as controls. Baseline age, sex, and comorbidity prevalence were all balanced.

Adjusted analysis revealed that exposure to antibiotics increased the likelihood of asthma development by more than three times (adjusted odds ratio [aOR], 3.68, 95 percent confidence interval [CI], 2.13–6.36). This effect was particularly strong for those under the age of 5 years (aOR, 4.14, 95 percent CI, 2.24–7.64).

Looking at specific types of antibiotics, significant risk elevations were observed with penicillin (aOR, 1.71, 95 percent CI, 1.37–2.14), cephalosporins (aOR, 1.36, 95 percent CI, 1.11–1.66), and macrolides (aOR, 1.51, 95 percent CI, 1.31–1.75).

Moreover, the impact of antibiotic use on asthma risk seemed to be dose-dependent. Those who had taken the highest cumulative defined daily dose (DDD) of penicillin (>14.75), cephalosporins (>6.68), and macrolides (>4.29) were more likely to develop asthma.

“[W]e concluded that frequent use of antibiotics in AD patients might exacerbate the subsequent development of asthma. The antibiotic subtype, dose, and duration of use should be taken into consideration when AD patients have infections,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 05 Apr 2021

Primary analysis of the D8110C00001 trial showed that the COVID-19 vaccine AZD1222 had 76 percent efficacy at preventing symptomatic COVID-19.

Roshini Claire Anthony, 12 Apr 2021

Treatment with the human monoclonal antibody tezepelumab reduced exacerbations and improved asthma control, lung function, and quality of life in adults and adolescents with severe, uncontrolled asthma, according to the phase III NAVIGATOR study presented as a poster at AAAAI 2021.

Audrey Abella, 16 Mar 2021
Following the administration of the first dose of the Pfizer-BioNTech COVID-19 vaccine between December 14 and 23, 2020 in the US, 21 cases of anaphylaxis have been recorded, equating to an initial estimated rate of 11.1 cases/million doses administered, according to a joint report from the US FDA and the CDC* COVID-19 Response Team.
Pearl Toh, 28 Apr 2021
Impaired smell function occurs more commonly in people with mild rather than moderate-to-critical forms of COVID-19 illness, a study finds.